10x Genomics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for 10x Genomics, Inc. (TXG) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-182.63-255.10-166.00-58.22-542.73-31.25
Depreciation & Amortization43.7143.6233.0128.2519.047.17
Stock Based Compensation140.75166.95136.8595.9648.630.00
Change in Working Capital1.2517.34-34.11-87.45-24.008.81
Change in Accounts Receivable26.95-10.61-18.95-34.04-17.850.00
Change in Inventory-9.787.87-21.19-30.13-14.600.00
Change in Accounts Payable-3.35-6.025.8611.08-7.770.00
Change in Other Working Capital-23.780.43-8.49-35.89-12.190.00
Other Operating Activities0.520.43132.380.08325.3143.99
Net Cash from Operating Activities6.66-15.20-33.61-21.37-217.9034.63
Investing Activities
Capital Expenditures-12.39-49.52131.66-101.2838.3942.77
Acquisitions0.000.00-4.00-5.450.000.00
Purchases of Investments-19.24183.02-215.230.000.000.00
Sales/Maturities of Investments-1.00183.02-215.230.00-1.730.00
Other Investing Activities-1.000.000.000.000.000.00
Net Cash from Investing Activities-32.63133.49-350.89-106.73-38.39-42.77
Financing Activities
Debt Repayment0.00-5.81-5.41-5.03-31.26-11.00
Common Stock Issued10.9119.4821.2340.33482.27410.82
Other Financing Activities0.00-5.81-5.41-5.030.000.00
Net Cash from Financing Activities10.9113.6715.8235.30468.91414.59
Summary
Effect of Forex Changes on Cash-0.16-0.03-0.040.23-0.46-0.05
Net Change in Cash-15.22131.96-368.68-92.81212.61406.45
Cash at Beginning of Period359.28227.35596.07688.64476.4970.09
Cash at End of Period344.07359.28227.35596.07688.64476.49
Free Cash Flow-5.73-64.72-165.27-122.65-256.29-8.14
Supplemental Disclosures
Interest Paid0.000.440.841.221.672.25
Income Taxes Paid5.644.933.938.660.280.02